Testing NCR102 for advanced gut GVHD
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new treatment called NCR102 for people with a severe form of graft-versus-host disease (GVHD) that affects the gut and hasn't responded to standard steroids or another line of therapy. The goal is to see if NCR102 can safely and effectively control the GVHD symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have moderate to severe gastrointestinal graft-versus-host disease (GVHD) that started after a stem cell transplant.
- Your GVHD has not improved after steroid treatment (called steroid-refractory).
- You have already tried a second-line treatment for GVHD and it didn't work.
- You do not have serious lung disease, liver disease, chronic GVHD, certain infections causing diarrhea, or active cancer in the last 5 years.
- You do not have known severe allergies to blood products or foreign proteins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This trial tests a combination of a steroid and a humanized antibody (called CD25 monoclonal antibody) as the first treatment for moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if this combination is safer and more effective than steroids alone.
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.